平成１３年度内分泌攪乱化学物質のヒトへの健康影響調査研究報告書
|
|
|
- たみえ かに
- 5 years ago
- Views:
Transcription
1 . 1, NB-1 MCF7 MEIC NB-1 JCRB Japan Cancer Research Bank MCF ATCCAmerican Type Culture Collection
2 PVDF.22µm cellsml ,6 NB-1 48 MCF NB-15.6 MCF ph T-COD D-COD T-N DTN T-P DTP SS a IBP, Flutolanil, Pyroquilon, Isoprothiolane, Simetryn, Bromobutide 5 28 St.1 3 ODS (MCF7
3 1 4 3 St.2 St.7 St LRRRYR 24 milliosmolel -1, ph NOEC NOEC ODS
4 ph LR RRYR NOEC µgl µg L -1 1 ODS 3
5 1) Clemedson, C., Kunimoto, M. et al. (1996) MEIC evaluation of acute systemic toxicity for the first 3 reference chemicals: Part I. Methodology of the 68 in vitro toxicity assays, ATLA, 24, ) Clemedson, C., Kunimoto, M. et al. (1996) MEIC evaluation of acute systemic toxicity for the first 3 reference chemicals: Part II. In vitro results from 68 methods and comparative cytotoxicity analysis, ATLA, 24, ) Ekwall, B., Kunimoto, M. et al. (1998) MEIC evaluation of acute systemic toxicity: Part. The prediction of human toxicity by rodent LD values and results from 61 in vitro methods, ATLA, 26, ) (21) 24, ) 21 24, ) (1997) 2, ) (1991). 8) (21)
6
7 CO 4 CO
8 NB-1 MCF7 NB-1 MCF7 St.2 St.2 Relative CellSurvival (%) St St.9 Relative CellSurvival (%) St St Month in Month in 2
9 Concentration (µgl -1 ) Phycocyanin B B B B B B B B B HJ H H H B B J J B J J J H H H H H H J J H H J J J J COD B B B B H B B B B B J J J J JB H H H J J J J J H HHH HHB B H HJ J T-N B B J B J B B B B B J J B H B B J J J J J J H H H H H B H J J H H H H H T-P B B B B B B B H B H B J J J B B J J H J J J H H J B H J J H H J H H H H B J H St.2 St.7 St Month in 2 Concentration (µgl -1 ) St.2 H F F B É H F ÑF É B J Ñ B J J H H ÉÑ ÉÑ J St B É Ñ F F F B J ÉÑ B F HB HJ ÉÑ HJ ÉÑ HJB Month in 2 B IBP F Isoprothiolane J Flutolanil Ñ Simetryn H Pyroquilon É Bromobutide
10 Relative Cell Survival (%) U.W. U.F. ODS A.C. C.E. A.E.
11
12 99/4 NB-1 MCF7 Relative Cell Survival (4% ) / / Sampling Point (St.NO., K=Kogan)
13 99/7 NB-1 MCF7 Relative Cell Survival (4% ) / / Sampling Point (St.NO., K=Kogan)
14 99/1 NB-1 MCF7 Relative Cell Survival (4% ) / / Sampling Point (St.NO., K=Kogan)
15 /1 NB-1 MCF7 Relative Cell Survival (4% ) K / K / K Sampling Point (St.NO., K=Kogan)
16 /4 NB-1 MCF7 Relative Cell Survival (4% ) K / K / K Sampling Point (St.NO., K=Kogan)
17 /7 NB-1 MCF7 Relative Cell Survival (4% ) K / K / K Sampling Point (St.NO., K=Kogan)
18 /1 NB-1 MCF7 Relative Cell Survival (4% ) K / K / K Sampling Point (St.NO., K=Kogan)
19 St.1 NB-1 MCF7 St.2 NB-1 MCF7 St.3 NB-1 MCF St.4 NB-1 MCF7 St.6 NB-1 MCF7 St.7 NB-1 MCF St.8 NB-1 MCF7 St.9 NB-1 MCF7 St.11 NB-1 MCF St.12 NB-1 MCF7 K NB-1 MCF7 M.Q. NB-1 MCF N.D. N.D N.D. N.D N.D. N.D N.D. N.D N.D. N.D N.D. N.D
20 St.1 NB-1 MCF7 St.2 NB-1 MCF7 St.3 NB-1 MCF St.4 NB-1 MCF7 St.6 NB-1 MCF7 St.7 NB-1 MCF St.8 NB-1 MCF7 St.9 NB-1 MCF7 St.11 NB-1 MCF St.12 NB-1 MCF7 K NB-1 MCF7 M.Q. NB-1 MCF
21 St.1 NB-1 MCF7 St.2 NB-1 MCF7 St.3 NB-1 MCF St.4 NB-1 MCF7 St.6 NB-1 MCF7 St.7 NB-1 MCF St.8 NB-1 MCF7 St.9 NB-1 MCF7 St.11 NB-1 MCF St.12 NB-1 MCF7 K NB-1 MCF7 M.Q. NB-1 MCF
22 St.1 NB-1 MCF7 St.2 NB-1 MCF7 St.3 NB-1 MCF St.4 NB-1 MCF7 St.6 NB-1 MCF7 St.7 NB-1 MCF St.8 NB-1 MCF7 St.9 NB-1 MCF7 St.11 NB-1 MCF St.12 NB-1 MCF7 K NB-1 MCF7 M.Q. NB-1 MCF
23 St.1 NB-1 MCF7 St.2 NB-1 MCF7 St.3 NB-1 MCF St.4 NB-1 MCF7 St.6 NB-1 MCF7 St.7 NB-1 MCF St.8 NB-1 MCF7 St.9 NB-1 MCF7 St.11 NB-1 MCF St.12 NB-1 MCF7 K NB-1 MCF7 M.Q. NB-1 MCF
24 St.1 NB-1 MCF7 St.2 NB-1 MCF7 St.3 NB-1 MCF St.4 NB-1 MCF7 St.6 NB-1 MCF7 St.7 NB-1 MCF St.8 NB-1 MCF7 St.9 NB-1 MCF7 St.11 NB-1 MCF St.12 NB-1 MCF7 K NB-1 MCF7 M.Q. NB-1 MCF
25 St.1 NB-1 MCF7 St.2 NB-1 MCF7 St.3 NB-1 MCF St.4 NB-1 MCF7 St.6 NB-1 MCF7 St.7 NB-1 MCF St.8 NB-1 MCF7 St.9 NB-1 MCF7 St.11 NB-1 MCF St.12 NB-1 MCF7 K NB-1 MCF7 M.Q. NB-1 MCF
26 St.1 NB-1 MCF7 St.2 NB-1 MCF7 St.3 NB-1 MCF St.4 NB-1 MCF7 St.6 NB-1 MCF7 St.7 NB-1 MCF St.8 NB-1 MCF7 St.9 NB-1 MCF7 St.11 NB-1 MCF St.12 NB-1 MCF7 K NB-1 MCF7 M.Q. NB-1 MCF
27 St.1 NB-1 MCF7 St.2 NB-1 MCF7 St.3 NB-1 MCF St.4 NB-1 MCF7 St.6 NB-1 MCF7 St.7 NB-1 MCF St.8 NB-1 MCF7 St.9 NB-1 MCF7 St.11 NB-1 MCF St.12 NB-1 MCF7 K NB-1 MCF7 M.Q. NB-1 MCF
28 St.1 NB-1 MCF7 St.2 NB-1 MCF7 St.3 NB-1 MCF St.4 NB-1 MCF7 St.6 NB-1 MCF7 St.7 NB-1 MCF St.8 NB-1 MCF7 St.9 NB-1 MCF7 St.11 NB-1 MCF St.12 NB-1 MCF7 K NB-1 MCF7 M.Q. NB-1 MCF
29 St.1 NB-1 MCF7 St.2 NB-1 MCF7 St.3 NB-1 MCF St.4 NB-1 MCF7 St.6 NB-1 MCF7 St.7 NB-1 MCF St.8 NB-1 MCF7 St.9 NB-1 MCF7 St.11 NB-1 MCF St.12 NB-1 MCF7 K NB-1 MCF7 M.Q. NB-1 MCF
30 St.1 NB-1 MCF7 St.2 NB-1 MCF7 St.3 NB-1 MCF St.4 NB-1 MCF7 St.6 NB-1 MCF7 St.7 NB-1 MCF St.8 NB-1 MCF7 St.9 NB-1 MCF7 St.11 NB-1 MCF St.12 NB-1 MCF7 K NB-1 MCF7 M.Q. NB-1 MCF
1 239 1 1 1 1 1 50 50 2 2 2 1 J1 G 2 20 50 J L AF 2 Y B 2 1 0 20 25 50 3 20 2 50 1 20 50 2 1 1 5 111 115 5 11 11 1 1 5 5 5 1 5 1 5 211 215 2 2 3 3 2 1 5 50 0 50 5 115 2 2 00 5 2 2 252 0 0 1 1 150 13 0
発達障害研修講座(1)
1. 2. 3. 4. 5. 6. 7. T 1. 2. 3. 4. 5. 6. 7. (1) (2) SST NPO LD SC http://www.ed.niigata-u.ac.jp/~nagasawa/challenge(2009).htm (1) (2) MT ST SST SST (2009) SS Human Sexuality) http://www.ed.niigata-u.ac.jp/~nagasawa/
ビジネス交渉術入稿.indd
Part1 1 1 6 1 2 8 1 3 10 1 4 12 1 5 14 Part1 16 Part2 Part2 Part3 2 1 18 2 2 20 2 3 22 2 4 24 2 5 26 2 6 28 2 7 30 2 8 32 2 Contents 2 9 34 2 10 36 2 11 38 40 Part3 3 1 42 3 2 44 3 3 46 3 4 48 3 5 50 3
Microsoft Word - 01マニュアル・入稿原稿p1-112.doc
4 54 55 56 ( ( 1994 1st stage 2nd stage 2012 57 / 58 365 46.6 120 365 40.4 120 13.0 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 4 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97
No ii
2005 6 1 2 200004 103/7-2000041037-1 3 4 5 JIS JIS X 0208, 1997 o È o http://www.pref.hiroshima.jp/soumu/bunsyo/monjokan/index.htm 200004 3 6 188030489521435 6119865 1220007 2 1659361903 3118983 16 381963
![.V...z.\](/thumbs/40/20575037.jpg ".V...z.\")
... 1... 2... 9... 20... 23 - i - ... 30... 34... 38 - ii - - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - 10 (A) (B) (A)(B) (C) (E) (C)(E) 16 3,096 3,700 6,796 975 5,821 17 3,002 4,082 7,084
ワタベウェディング株式会社
1 2 3 4 140,000 100,000 60,000 20,000 0 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 5 6 71 2 13 14 7 8 9 10 11 12 1 2 2 point 1 point 2 1 1 3 point 3 4 4 5 6 point 4 point 5 point 6 13 14 15 16 point 17
ヤフー株式会社 株主通信VOL.16
01 260,602264,402 122,795125,595 64,84366,493 107110 120,260123,060 0 500 300 400 200 100 700 600 800 39.8% 23.7% 36.6% 26.6% 21.1% 52.4% 545 700 0 50 200 150 100 250 300 350 312 276 151 171 02 03 04 POINT
p01.qxd
2 s 1 1 2 6 2 POINT 23 23 32 15 3 4 s 1 3 2 4 6 2 7003800 1600 1200 45 5 3 11 POINT 2 7003800 7 11 7003800 8 12 9 10 POINT 2003 5 s 45700 3800 5 6 s3 1 POINT POINT 45 2700 3800 7 s 5 8 s3 1 POINT POINT
株主通信：第18期 中間
19 01 02 03 04 290,826 342,459 1,250,678 276,387 601,695 2,128,760 31,096 114,946 193,064 45,455 18,478 10,590 199,810 22,785 2,494 3,400,763 284,979 319,372 1,197,774 422,502 513,081 2,133,357 25,023
1003shinseihin.pdf
1 1 1 2 2 3 4 4 P.14 2 P.5 3 P.620 6 7 8 9 10 11 13 14 18 20 00 P.21 1 1 2 3 4 5 2 6 P7 P14 P13 P11 P14 P13 P11 3 P13 7 8 9 10 Point! Point! 11 12 13 14 Point! Point! 15 16 17 18 19 Point! Point! 20 21
untitled
1 2 3 4 5 6 7 Point 60,000 50,000 40,000 30,000 20,000 10,000 0 29,979 41,972 31,726 45,468 35,837 37,251 24,000 20,000 16,000 12,000 8,000 4,000 0 16,795 22,071 20,378 14 13 12 11 10 0 12.19 12.43 12.40
株主通信 第16 期 報告書
10 15 01 02 1 2 3 03 04 4 05 06 5 153,476 232,822 6,962 19,799 133,362 276,221 344,360 440,112 412,477 846,445 164,935 422,265 1,433,645 26,694 336,206 935,497 352,675 451,321 1,739,493 30,593 48,894 153,612
![[商品カタログ]ゼンリン電子地図帳Ｚｉ16](/thumbs/48/24409875.jpg "[商品カタログ]ゼンリン電子地図帳Ｚｉ16")
-- 0 500 1000 1500 2000 2500 3000 () 0% 20% 40% 60%23 47.5% 16.0% 26.8% 27.6% 10,000 -- 350 322 300 286 250 200 150 100 50 0 20 21 22 23 24 25 26 27 28 29 -- ) 300 280 260 240 163,558 165,000 160,000
CAS NC(CH 2 ) 4 CN 1,4- C 6 H 8 N c.c d = Pa
1 200117 21512 CAS 111693 110 NC(CH 2 ) 4 CN 1,4- C 6 H 8 N 2 108.14 1 99 2-1. 2 1 295 159 c.c. 550 3 1.7-4.9 20 d 0.965 4 3.73 = 1 0.3 Pa 0.002 mmhg20 2 log Pow-0.32 m/z 41, 1.0 68 0.54 54 0.43 4 Koc9-16
有明海･八代海総合調査評価委員会－中間取りまとめ－
COD 1 15 B-3() St.7() B-2() A-2() St.9() St.1() B-2() B-1() 13 16 4 2 3 5 6 7 () St.7() St.9() 12 11 8 () 9 1 Km 1K St-1() St-7() 5() 7 () COD T-N T-P SS St.7() St.9() St.1() St.7() + St.9() () () A-2()
2 7 ( ) µ 
ê ê ê 2007 ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê b b b b b b b b b b b ê ê ê b b b b ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê ê b
CompuSec SW Ver.5.2 アプリケーションガイド（一部抜粋）
64 PART 9 65 66 PART10 67 1 2 3 68 PART 10 4 5 69 1 2 3 4 5 70 PART 10 6 7 8 6 9 71 PART11 72 PART 11 1 2 3 73 4 5 6 74 PART 11 7 8 9 75 PART12 76 PART 12 1 2 3 4 1 2 3 4 77 1 2 3 4 5 6 7 8 78 PART13 79
65歳雇用時代の賃金制度のつくり方
1 65 2005 2 65 18 65 2 PART 165 6 7 8 11 14 16 60 17 25 PART 2 28 35 () 10 35 () 35 () 36 () 39 () 39 () 41 () 42 () 42 () 44 (10) 44 (11) 47 1 15 2007 2 35 3 10 10 2.5 2.5 1.5 0.5 2.5 2.5 1.5 0.5 10
Microsoft Word - p2-11堀川先生_紀要原稿_ final.doc
u 0Q w ÎÈÉg fêf 2008 uê Êfu ÉÈÉÆÍÌÊÊÊÇÊ ÃuwÊ ÃÉÃÊfÃÇÆÍÂÇÍÊ ~ÈÉ ÎÈÍÇÉÇÍÇ ÈÍÍÇ ÎÈÍÉÊÊÆÆÆÇÉÇÊvxÊÆÂ É ÆÆ ÌyÎÈÍÉÇÉÊÇ ÌyÎÈÍÿ~ÊÔÖÑÑÉ ÈÇÉuÊÈÌÈÌÊÊÑÐÖÎg fèíçéçuéæíâèíêí ÉÉ ÊÃÎÆÃÎÆ ÌÉÆÊÌÉÇÍÍÆÊÊÍÂ ÊÊ ÈÉ Ãfu ÃÊÊ 1
3, ,104 t mg/l 30 mg/l BOD mg 14 C 8, /kg 11 8, 1 11 OH = cm 3 / sec 11 OH /cm ppm
3, 3-1 200019 4800 CAS 91941 1138 3, 3-4, 4 - -3, 3 - H 2 N Cl Cl NH 2 C 12 H 10 C l2 N 2 253.13 1 95 1. 2 3, 4 132-133 402 5 >200 5 700kg/m 3 5 8.73 = 1 5.610-8 kpa 4.210-7 mmhg20 4 6 log Pow3.51 3.57
橡96-07.PDF
1 967 2482 CAS 50000 CH 2 O 30.03 2952% 12.5 % 1. 2) -92 2) -19.5 2) 5085 3) 424 3) 7.073.0% 4) 20 d 4 0.815 5) 1.03 ( = 1) 5) 1.33 kpa (10 mmhg) (-88.0) 2) log Pow0.35 ( ) 6) 0.35 ( ) 7) 1) m/z 29 ( 1.0
t 492 t mg/l 30 mg/l BOD 95 OH = cm 3 / sec 25 8 OH /cm 3 12 = ph ph
2-1 200169 2740 CAS 110-49-6 1103 2- O H 3 C C O CH 2 CH 2 O CH 3 C 5 H 10 O 3 118.13 200168 2-1 99 2-1. 2 2, 3-65 2, 3 144145 45 o.c. 3 392 3 1.512.3 d19 1.009 2 4.07 = 1 30 Pa 0.23 mmhg20 2 4 log Pow0.10
3 4 6 7 8 9 10 12 14 2 3
3 4 6 7 8 9 10 12 14 2 3 POINT 4 5 3053 1323 4 7 6 1 1 4 7 Yamada N. et al : Int J Cardiol. 98, 409-411, 2005 6 7 POINT 0 20 40 60 80 100 60 80 Ota M. et al: Heart Vessels. 17, 7-11,2002 40 60 20 50 15
CAS H 3 C C CH 2 C 9 H tert d = hpa
1 200140 35 CAS 98839 1335-2- H 3 C C CH 2 C 9 H 10 118.18 1 99 4-tert- 1. 2-23.2 2 163164 2 54 574 3 0.96.6 20 d 4 0.9082 2 4.07 = 1 2.5 hpa 1.9 mmhg20 2 4 log Pow3.48 3.44 m/z 118, 1.0 103 0.58 91 0.21
ブック 1.indb
20 29 29 18 21 29 10 30 31 10 11 12 30 13 10 30 14 11 30 15 12 16 13 17 14 18 15 19 16 20 17 21 18 10 20 29 82 83 84 85 86 87 88 20 10 89 20 12 11 90 20 13 12 91 20 14 13 92 20 14 14 93 15 15 94 15 16
C-1 210C f f f f f f f f f f f f f f f f f f f f r f f f f f f f f f f f f f R R
4 5 ff f f f f f f f f f f f f ff ff ff r f ff ff ff ff ff ff R R 7 b b ï φφ φφ φφ φ φ φφ φφφφφφφφ φφφφ φφφφ ù û û Æ φ ñ ó ò ô ö õ φφ! b ü ú ù û ü ß μ f f f f f f f f f f b b b z x c n 9 f φ φ φ φ φ φ
ï ñ ö ò ô ó õ ú ù n n ú ù ö ò ô ñ ó õ ï
ï ñ ö ò ô ó õ ú ù n n ú ù ö ò ô ñ ó õ ï B A C Z E ^ N U M G F Q T H L Y D V R I J [ R _ T Z S Y ^ X ] [ V \ W U D E F G H I J K O _ K W ] \ L M N X P S O P Q @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ r r @ @
128 Q2. LCCO 2 LCCO CO 2 CO 2
127 LR3 LR35 LR3 1. CO 2 CO 2 CO 2 CO 2 CO 2 CO 2 CO 2CO 2 LCCO 2 LCCO 2 CASBEE PART LCCO 2 LCCO 2 CO 2 LR2. CO 2 embodied CO 2 LR1. BEICO 2 128 Q2. LCCO 2 LCCO 2 60 30 30 60 90 CO 2 CO 2 129 2. 2.1 5
AC-2
AC-1 AC-2 AC-3 AC-4 AC-5 AC-6 AC-7 AC-8 AC-9 * * * AC-10 AC-11 AC-12 AC-13 AC-14 AC-15 AC-16 AC-17 AC-18 AC-19 AC-20 AC-21 AC-22 AC-23 AC-24 AC-25 AC-26 AC-27 AC-28 AC-29 AC-30 AC-31 AC-32 * * * * AC-33
エンジョイ北スポーツ
28 3 20 85132 http://www.kita-city-taikyo.or.jp 85 63 27 27 85132 http://www.kita-city-taikyo.or.jp 2 2 3 4 4 3 6 78 27, http://www.kita-city-taikyo.or.jp 85132 3 35 11 8 52 11 8 2 3 4 1 2 4 4 5 4 6 8
学会誌カラー（目次）／目次１１‐１１月
! Σ ! ! " # $ % & ' '! ! " # !! !!! !!!!!! On the Committee for Disputes Solution on the Atomic Damages in Japan The Legal Scheme and the Guideline making about the Damages from the Accident of FukushimaAtomic
,977 t 157,977 t mg l mg l BOD 9398 % OH = cm 3 / sec 11 = cm 3 / sec OH = /
1 9625 2219 CAS 75569 1, 2-1, 2- H 2 C CH CH 3 C 3 H 6 O 58.08 1 99 % 1. 2 2, 3-112.13 2, 3 34.23-37 449 2.8-37 % 2 d 0 4 0.859 4 d 20 0.8304 2 2, 4 2.00 = 1 53.33 kpa 400 mmhg18 59.33 kpa 445 mmhg20 5
,309 t 22,069 t 7,240 t µg/l µg/l < ,431-70, , , mg/l m
1 20019 1527 CAS 1317368 1230 PbO 223.20 1 99 1. 2 888 2 9.53 0.017 g/l 20 3 3 2 2. 10 29,309 t 22,069 t 7,240 t 4 1 3. 1 2 3.5 6 1 µg/l 9.1-24 2 µg/l < 43 6 27,431-70,000 4.5-1,300 13.4-17 31.7 0.48-3,459
橡99-24_00 アリルアルコール.PDF
1 9924 2260 CAS 107186 H 2 C CH CH 2 OH 2- -1- C 3 H 6 O 58.08 1 99 1. 2, 3 3, 4, 5-129 96-97 2 21c.c. 24o.c. 2 6, 7 378 6, 7 2.5-18 d 20 4 0.8540 2, 5 2.00 = 1 2.7 kpa 20 mmhg204.3 kpa 32 mmhg30 4 log
A B ( +A+B) H g H27 H28 H29 H30 189, , , , , , , , ,
04 01 03 01 001505000 30 7 1 30 10 A B (+A+B) H36 11 g 851 30.1 H27 H28 H29 H30 189,405 160,401 149,683 138,928 165,746 133,618 125,755 107,100 103,700 96,700 96,700 272,846 237,318 222,455 235,628 H27
http://keirin.jp ...1 1....2 1.1...2 1.1.1...2 1.1.2...4 1.2...5 1.2.1...6 1.2.2...7 1.3...11 1.3.1...11 1.3.2...12 2....14 2.1...14 2.2...17 2.2.1 5...17 2.2.2...20 3....27 3.1...27 3.1.1...27 3.1.2...35
